Pasithea Therapeutics (KTTA) News Today $0.70 -0.07 (-8.75%) Closing price 04:00 PM EasternExtended Trading$0.70 -0.01 (-1.08%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KTTA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Pasithea Therapeutics (NASDAQ:KTTA) Stock Price Down 1.3% - Here's WhyMay 19 at 2:43 AM | americanbankingnews.comPasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical OfficerMay 4, 2026 | globenewswire.comIs Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?May 3, 2026 | finance.yahoo.comPasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)April 20, 2026 | markets.businessinsider.comPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN ...April 1, 2026 | markets.businessinsider.comPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant MorbidityApril 1, 2026 | globenewswire.comPasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference TranscriptFebruary 27, 2026 | seekingalpha.comPasithea Therapeutics Corp. to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026February 17, 2026 | quiverquant.comQPasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 17, 2026 | globenewswire.comPasithea Therapeutics Shareholders Approve Expanded Equity AuthorizationJanuary 28, 2026 | tipranks.comPasithea Therapeutics Updates Clinical Trial Timelines for PAS-004 in Neurofibromatosis and Advanced CancerJanuary 13, 2026 | quiverquant.comQPasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release TimelinesJanuary 13, 2026 | globenewswire.comPasithea Therapeutics (KTTA) price target increased by 50.00% to 3.06December 21, 2025 | msn.comPasithea Therapeutics Regains Nasdaq ComplianceDecember 15, 2025 | tipranks.comHC Wainwright & Co. initiates coverage of Pasithea Therapeutics (KTTA) with buy recommendationDecember 8, 2025 | msn.comLawrence Steinman Bought 201% More Shares In Pasithea TherapeuticsDecember 4, 2025 | finance.yahoo.comInsiders Buying Pasithea Therapeutics Might Wish They Invested More, Stock Gains 10%December 4, 2025 | finance.yahoo.comPasithea Therapeutics Announces Closing of $60 Million Public Offering of Common StockDecember 2, 2025 | markets.businessinsider.comPasithea Therapeutics Announces Closing of $60 Million Public Offering of Common StockDecember 2, 2025 | globenewswire.comPasithea Therapeutics (NASDAQ:KTTA) Director Simon Dumesnil Purchases 33,333 SharesDecember 2, 2025 | insidertrades.comPasithea Therapeutics prices 80M shares at 75c in public offeringNovember 28, 2025 | msn.comPasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common StockNovember 28, 2025 | markets.businessinsider.comPasithea Therapeutics Corp. Completes Public Offering to Extend Cash Runway through First Half of 2028November 28, 2025 | quiverquant.comQPasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common StockNovember 28, 2025 | globenewswire.comPasithea Therapeutics Reports Positive Phase 1 Data for PAS-004November 25, 2025 | msn.comPasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALSNovember 25, 2025 | finance.yahoo.comPasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and ...November 24, 2025 | markets.businessinsider.comPasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) DataNovember 24, 2025 | globenewswire.comPasithea says tablet PK exposure increases proprtionally with dose increaseNovember 21, 2025 | msn.comPasithea Therapeutics Reports Positive Phase 1/1b Pharmacokinetic Data for PAS-004 Tablet Formulation in Neurofibromatosis Type 1 PatientsNovember 21, 2025 | quiverquant.comQPasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 PatientsNovember 21, 2025 | globenewswire.comPasithea Therapeutics stock plunges after Phase 1 interim data releaseNovember 21, 2025 | in.investing.comPasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in ...November 21, 2025 | finance.yahoo.comPasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer StudyNovember 20, 2025 | globenewswire.comPasithea announces activation of trial site at UAB for study of PAS-004November 4, 2025 | msn.comPasithea Therapeutics Activates New Clinical Trial Site at UAB for PAS-004 Study in Neurofibromatosis Type 1 PatientsNovember 4, 2025 | quiverquant.comQPasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsNovember 4, 2025 | globenewswire.comPasithea Therapeutics announces activation of two South Korean trial sitesSeptember 16, 2025 | msn.comPasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsSeptember 16, 2025 | globenewswire.comPasithea announces enrollment of cohort 2 in Phase 1/1b trial of PAS-004September 8, 2025 | msn.comPasithea Therapeutics Receives Recommendation to Escalate Phase 1/1b Trial of PAS-004 to 8mg Dose LevelSeptember 8, 2025 | quiverquant.comQPasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 29, 2025 | globenewswire.comPasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 28, 2025 | markets.businessinsider.comPasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsJuly 31, 2025 | globenewswire.comKTTA Pasithea Therapeutics Corp. - Seeking AlphaJuly 25, 2025 | seekingalpha.comPasithea Therapeutics schedules 2025 annual meeting for September 3July 13, 2025 | investing.comPasithea Therapeutics Appoints Dr. James Lee to Scientific Advisory Board to Advance PAS-004 Development for Inflammatory DiseasesJune 12, 2025 | nasdaq.comPasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory BoardJune 11, 2025 | globenewswire.comPasithea Therapeutics Reports Promising Interim Results for PAS-004 in Phase 1 Trial for Refractory Solid Tumors at ASCO 2025June 4, 2025 | nasdaq.comPasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025June 2, 2025 | globenewswire.com Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KTTA Media Mentions By Week KTTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KTTA News Sentiment▼1.500.37▲Average Medical News Sentiment KTTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KTTA Articles This Week▼22▲KTTA Articles Average Week Get the Latest News and Ratings for KTTA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Pasithea Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Spruce Biosciences News Seres Therapeutics News Gain Therapeutics News Clene News ImmuCell News PMV Pharmaceuticals News Coeptis Therapeutics News BioHarvest Sciences News Rallybio News Pliant Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KTTA) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
